KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $1.0 billion.

  • Teva Pharmaceutical Industries' Other Accumulated Expenses fell 11.12% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 11.12%. This contributed to the annual value of $1.0 billion for FY2024, which is 2.30% down from last year.
  • Teva Pharmaceutical Industries' Other Accumulated Expenses amounted to $1.0 billion in FY2024, which was down 2.30% from $1.0 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Other Accumulated Expenses' 5-year high stood at $1.0 billion during FY2023, with a 5-year trough of $903.0 million in FY2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.0 billion (2024), whereas its average is $1.0 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Other Accumulated Expenses dropped by 3.22% in 2021, and later increased by 11.30% in 2022.
  • Teva Pharmaceutical Industries' Other Accumulated Expenses (Yearly) stood at $933.0 million in 2020, then decreased by 3.22% to $903.0 million in 2021, then grew by 11.30% to $1.0 billion in 2022, then rose by 3.88% to $1.0 billion in 2023, then decreased by 2.30% to $1.0 billion in 2024.